Sponsored Links
| Inovio Pharmaceuticals Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine |
 |
 |
 |
| Medical News - Cervical Cancer HPV | |||
|
Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV)... Read more: Cervical Cancer / HPV Vaccine News From Medical News Today
|